Tools
Stock profile

Indivior Pharmaceuticals, Inc. (INDV)

INDV · Latest close — as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
Data unavailable
No price in range
Tracked funds holding
2 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
3
vs previous quarter

Indivior Pharmaceuticals, Inc. (INDV) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 3 funds trimming or exiting versus the previous quarter. Insiders were net buyers over the last 90 days ($53.5K bought vs $0 sold).

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Aug 27, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $53.5K
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Oaktree Capital Management · Deerfield Management — 2 tracked funds hold INDV. See all holders.

Insider and Congress activity

Insiders bought on the open market (1 purchase, $53.5K) vs 0 sales ($0). Latest buy: Aug 27, 2026. Insider trading

Often held alongside

Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Oaktree Capital Management3.49%6,127,212TRIMMED (-12.3%)
Deerfield Management0.71%1,648,895TRIMMED (-46.8%) Q3 filed Nov 16
Rubric Capital Management——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -9.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 2, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

41.836.912024-11-042026-11-02

Closing prices (unadjusted for dividends), last 2 years — 500 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding335 of 8,857 filers
Long-only filers among them335
Change vs 2026 Q1+50 net · 323 entered · 273 exited
Shares reported, all filers121,290,651
Reported value, all filers$4.9B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$1.2B
Net income · FY2025$210.0M
Total assets · FY2025$1.2B
Shares outstanding118,035,272

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 9, 2026.

Short interest

Shares short · Oct 15, 20269,414,157
Share of shares outstanding7.98%
Days to cover3.38

Shares short at recent settlements — Jul 31, 2026: 10.9M · Aug 14, 2026: 10.4M · Aug 31, 2026: 11.3M · Sep 15, 2026: 11.2M · Sep 30, 2026: 10.4M · Oct 15, 2026: 9.4M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 9, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20267,780
Share of shares outstanding0.01%
Fails as a share of short interest · Oct 15, 2026<0.1%

Fails to deliver at recent settlements — Jul 31, 2026: 12K · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 5K · Oct 14, 2026: 8K.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 9, 2026.

Insider trading · Form 4

1 insider bought on the open market in the last 90 days (1 purchase, $53.5K), against 0 sales by 0 insiders ($0). Latest buy: Aug 27, 2026.

Source: SEC Form 4 filings. Open-market transactions only.

Latest open-market buyTransaction pricePrice change since disclosure
Anderson Woodrow D · 1,500 shares on Aug 27, 2026 · filed Aug 27, 2026$35.69+4.0% (close Aug 28, 2026 → Nov 2, 2026)

Reference close is the first trading day after the filing (Aug 28, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Aug 27, 2026Anderson Woodrow DChief Accounting OfficerBuy1,500$35.69$53.5KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Jul 10, 2026Heidbreder ChristianOfficer18,586$764.6KJul 10, 2026SEC filing
Jun 11, 2026Heidbreder ChristianOfficer18,586$707.4KJun 11, 2026SEC filing
Jun 8, 2026Preblick RyanOfficer36,000$1.4MJun 8, 2026SEC filing
Jun 8, 2026Preblick RyanOfficer36,000$1.4MJun 8, 2026SEC filing
Nov 7, 2025Cetani Cynthia COfficer121,737$3.7MNov 7, 2025SEC filing
Sep 8, 2025Crossley MarkAffiliate26,463$655.0KSep 8, 2025SEC filing
Sep 8, 2025Mark Crossleyaffiliate183,938$4.6MSep 8, 2025SEC filing
Sep 4, 2025Mark Crossleyaffiliate30,000$744.0KSep 4, 2025SEC filing
Aug 28, 2025Mark Crossleyaffiliate52,320$1.3MAug 28, 2025SEC filing
Mar 20, 2024Heidbreder ChristianOfficer6,284$132.4KMar 13, 2024SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Aug 13, 2026SCHEDULE 13D/A-7.0% (close Aug 14, 2026 → Nov 2, 2026)

Reference close is the first trading day after the filing (Aug 14, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Sep 30, 2026Millennium Management LLCSC 13G6,343,6515.4%Sep 23, 2026SEC filing
Aug 13, 2026Oaktree Value Opportunities Fund, L.P.SC 13D/A385,0370.3%Aug 11, 2026SEC filing
May 15, 2026Madison Avenue International LPSC 13G/A4,315,1623.5%Mar 31, 2026SEC filing
May 13, 2026Fuller & Thaler Asset Management, Inc.SC 13G/A4,529,583.473.7%Mar 31, 2026SEC filing
Apr 28, 2026Vanguard Portfolio ManagementSC 13G7,994,8366.5%Mar 31, 2026SEC filing
Apr 27, 2026Vanguard Capital ManagementSC 13G6,523,7205.3%Mar 31, 2026SEC filing
Mar 23, 2026Millennium Management LLCSC 13G4,806,5563.8%Mar 17, 2026SEC filing
Feb 17, 2026Fuller & Thaler Asset Management, Inc.SC 13G6,371,533.75.1%Dec 31, 2025SEC filing
Feb 17, 2026Madison Avenue International LPSC 13G/A6,280,5025.0%Dec 31, 2025SEC filing
Feb 12, 2026THE GOLDMAN SACHS GROUP, INC.SC 13G/A3,592,430.82.9%Dec 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 24 Lobbying Disclosure Act filings named this company as client, 2014–2016; most common issues: Health Issues (23), Pharmacy (23), Alcohol and Drug Abuse (22).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Insiders

· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions

Financial Screens

· Gross Profitability (Novy-Marx) — High gross profit relative to total assets

Red Flags

· Earnings Manipulation Suspect (Beneish) — Beneish M-Score above -1.78

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%

Key figures

· Gross Profitability (Novy-Marx) — Gross profit / assets: 82.8% · Gross margin: 80.2%

· Insider Net Buying — Buy txns: 1 · Sell txns: 0 · Buy value: $53.5K · Latest buy: Aug 27, 2026

· Earnings Manipulation Suspect (Beneish) — M-Score: -1.39 · Receivables index: 0.96 · Margin deterioration: 1.00 · Sales growth index: 1.04 · Accruals ratio: 19.7%

· Distress Risk (Altman Z″) — Z″-Score: -0.70 · Working capital / assets: -0.22 · Retained earnings / assets: -0.20 · EBIT / assets: 0.22 · Equity / liabilities: -0.08

· Excess Accruals (Sloan) — Accruals ratio: 25.2% · Net income: $210.0M · Operating cash flow: $-27.0M · Investing cash flow: $-66.0M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2026 Q1, ranked #8 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Share count tripled (3x)1100.0%+10.7%+2.9%+7.9%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold INDV — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 3, 20268.01 Other EventsSEC filing
Nov 2, 20261.01 Entry into a Material Definitive Agreement · 2.01 Completion of Acquisition or Disposition of Assets · 2.03 Creation of a Direct Financial Obligation · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Oct 29, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on INDV

One email a week: the week’s new filings and research. Subscribe free

← INDA  ·  INFQ →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.